Method Profile
Assembled skin and blood-vessel organoids with cord-blood immune cells link barrier, infiltration and STAT6-associated drug responses.
Preclinical evaluation of selected anti-inflammatory mechanisms in an atopic-dermatitis-relevant allergen response.
Human iPSC-derived skin/blood-vessel organoid modules combined under air–liquid-interface conditions and supplemented with mononuclear cells.
Compare allergen-exposed tissues with matched controls and upadacitinib/dupilumab conditions using barrier, immune and molecular endpoints.
Tissue modules
Stratified skin and interconnected vascular-like structures in static culture.
Immune/drug components
Independent cord-blood mononuclear-cell donors; upadacitinib and dupilumab.
Measurements
Histology, FLG/LOR/CLDN1/KRT16, upper-dermal CD4 cells, STAT6 phosphorylation, qPCR and cytokine profiles.
Connect spatial tissue changes with pathway-associated measurements; keep immune-cell identity and the static vascular arrangement explicit.
Compare house-dust-mite-associated inflammation with the two mechanistically distinct therapies.
One described hiPSC background; cord-blood donors are incorporated independently. Selected drug figures report n = 3 comparisons, which are not presented as three patient disease backgrounds.
Unstimulated controls, allergen/vehicle condition and each drug-treated condition.
Both therapies improved barrier-associated markers, reduced upper-dermal CD4 infiltration and decreased STAT6 phosphorylation and selected inflammatory signals.
Human skin and blood-vessel organoids were assembled with immune cells to study allergen-associated inflammation. Upadacitinib and dupilumab improved barrier-related markers and reduced STAT6-associated inflammatory signals.
